Skip to content

Effect of G6PD Deficiency on Red Blood Cell Storage

Effect of Glucose-6-phosphate Dehydrogenase Deficiency on Donor Red Blood Cell Storage

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04081272
Enrollment
40
Registered
2019-09-09
Start date
2012-11-30
Completion date
2017-10-31
Last updated
2019-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G6PD Deficiency

Keywords

transfusion, post-transfusion recovery

Brief summary

The proposed study will determine whether G6PD-deficient RBCs store differently than normal RBCs under standard blood banking conditions. The investigators plan to screen a large number of healthy male volunteers for G6PD deficiency in order to identify 10 G6PD deficient and 30 matched normal individuals using a blood sample obtained from a finger-stick. The identified individuals will then be asked to donate a unit of blood that will be stored for up to 42 days and various tests will be performed on these units during storage. At 6 weeks of storage a portion of the unit will be radioactively labeled and re-infused into the volunteer. Blood samples will be drawn before, during, and after the infusion to measure how well or poorly the red blood cells survive after transfusion.

Detailed description

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme deficiency, affecting approximately 400 million people world-wide. It manifests as red blood cell (RBC) destruction in response to oxidative stress, which can be precipitated by infection, and by the ingestion of certain medications and foods. The prevalence of G6PD deficiency varies among populations and is most commonly found in individuals from sub-Saharan Africa, the Mediterranean region, and south-east Asia. Although in most studies G6PD-deficient individuals have normal RBC survival at steady-state, this may vary based upon the G6PD variant present, and some individuals may have shortened RBC survival. While it is not routine practice to screen blood donors for G6PD deficiency, G6PD deficient donor RBCs may store more poorly than normal RBCs. In addition, the transfusion of stored G6PD-deficient RBCs may result in decreased RBC survival after transfusion compared to RBCs from normal donors.

Interventions

DRUGSodium Chromate Cr51

Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.

Sponsors

New York Blood Center
CollaboratorOTHER
Columbia University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Male * Weight greater than 110 pounds * Hemoglobin greater than 11.5 g/dL * African (e.g., Afro-American, Afro-Caribbean, Sub-Saharan), Asian, Hispanic, Middle Eastern, or Mediterranean (e.g., Italian, Greek) based on mother's ancestry * English speaking

Exclusion criteria

* Presence of hemoglobin variant * Ineligible for donation based on the New York Blood Center donor autologous questionnaire * Systolic blood pressure \>180 or \<90 mm Hg, diastolic blood pressure \>100 or \<50 mm Hg * Heart rate \<50 or \>100 * Temperature \>99.5°F prior to donation * Temperature \>100.4°F or subjective feeling of illness prior to transfusion (this criterion is to avoid concurrent illness affecting post-transfusion measurements) * Positive results on standard blood donor infectious disease testing

Design outcomes

Primary

MeasureTime frameDescription
24-hour post-transfusion red blood cell recovery24 hoursPercentage of radio-labeled red blood cells remaining 24 hours after infusion

Secondary

MeasureTime frameDescription
In vitro hemolysis rate42 daysPercent hemolysis in the red blood cell unit in vitro

Other

MeasureTime frameDescription
Number of samples with metabolites detectedPre-donation to 42 days after donationMetabolomics analysis: metabolites that are representative of major metabolic pathways will be measured in the red blood cells or supernatant during storage. Quantitative measurements will be performed using high performance liquid chromatography and mass spectrometry and the data obtained will be analyzed to detect correlations with the primary outcome measure of 24-hour post-transfusion red blood cell recovery.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026